We would love to hear your thoughts about our site and services, please take our survey here.
Also on April 1, 2022, Dr. Dilly met with a representative of a biopharmaceutical company, that we refer to as “Party G,” in connection with
ongoing discussions between Sierra Oncology and Party G regarding opportunities for licensing, partnership and other strategic transactions. As part of
the discussion, Dr. Dilly and the representative discussed on a preliminary basis the possibility of a business combination between Sierra Oncology and
Party G, but deferred further discussion to a future date.
Would the CTA application or even the C19 extended trial that were announced as on track to be progressed in firsts half of the year be in conclusion with any interested party? Only a few weeks before we find out.
Hi Horse, it was posted just before from a very reliable source and got lost after the GSK takeover, cant remember where, but i made a note that reads
CB = 1,009,521
JR = 965,832
TM= 809,521
Nothing on SP
I hope this helps GLA
Hi Nrd, GSK have Oncology, fingers and toes crossed they require SRA737 to move forward rapidly.
https://www.nature.com/articles/d42473-020-00457-6
Hopefully looking forward to the trials starting. Will GSK have a hand in this?
SRA737: A Selective Chk1 inhibitor (cancer)
During the second half of 2021 and early 2022, Sierra Oncology, Inc. (“Sierra”), the licence holder for SRA737, noted it is finalising the design of several potential clinical trials to advance its pipeline candidates, including SRA737, which could start in 2022. These trials are expected to investigate SRA737 in combination with other agents in haematologic and solid tumour indications
The dosing of the first patient with SRA737 in any new clinical trial would result in a $2.0m payment from Sierra under the amended $290m licensing deal on SRA737 between Sierra and CRT Pioneer Fund LP. Under the amended agreement, Sareum continues to be eligible to receive a 27.5% share of this and any future milestone payments as well as royalties on any future sales
T2 I can only echo the sentiments expressed on this board. Without your input and knowledge most of us would have sold up long ago at 2-3p old money.
I hope you get the support you fully deserve and I wish you all the very best.
No win no fee firm, common over the pond.
Halper Sadeh LLP represents investors who have fallen victim to securities fraud and corporate misconduct.
We use the litigation process to maximize the recovery of our clients’ investment losses, increase market transparency, improve corporate governance and business practices, and hold wrongdoers accountable.
We assume every case we litigate will proceed to trial. This enables us to recover a higher percentage of losses for our clients than is typical in securities fraud cases because, unlike other law firms, we are prepared and willing to take our cases to trial to achieve the maximum result obtainable for our clients.
Our attorneys are graduates of the Georgetown University Law Center and have collectively worked for prominent defense and securities class action law firms, the federal judiciary, the New Jersey Superior Court, Appellate Division, and the Attorney General for the District of Columbia. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
OUR FEES AND EXPENSES --- Our firm works on a contingency fee basis. That means our clients do not pay any attorneys' fees or expenses unless we secure a recovery or benefit on their behalf. Typically, if we are successful in securing a recovery or benefit, we will ask the court to grant us reimbursement of our reasonable out-of-pocket expenses and attorneys' fees. The court will assess the reasonableness of our fees and expenses and set them accordingly.
Could one theory be the patent RSN was a smoke screen to hide heavy buying as that news was posted by James days before yesterday’s announcement.
We all know the next bit of news will be good the question is how Google hmmmm
Could we be inline for the same fast track to trials ?
We have ticked many boxes in the past two years. Don’t forget the FOI request that was refused a few months back, we could be one of the companies bidding for government aid to move on swiftly.
GLA